In an adult with an elevated growth hormone level, what are the possible causes, how should it be evaluated (including IGF‑1 measurement, oral glucose tolerance test, and pituitary MRI), and what are the treatment options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Elevated Growth Hormone in Adults: Causes, Evaluation, and Treatment

Primary Cause and Initial Consideration

An elevated growth hormone level in an adult most commonly indicates acromegaly due to a GH-secreting pituitary adenoma (somatotrophinoma), which accounts for approximately 60% of cases when purely GH-secreting, with additional cases involving mixed hormone secretion. 1

Differential Diagnosis of Elevated GH

Pathological Causes

  • GH-secreting pituitary adenoma (somatotrophinoma): The predominant cause in the vast majority of cases 2, 1
  • Ectopic GHRH secretion: Rare tumors (particularly pancreatic neuroendocrine tumors in MEN-1 syndrome) secrete growth hormone-releasing hormone, causing pituitary hyperplasia 3
  • Genetic syndromes (more common in younger patients but can present in adults):
    • McCune-Albright syndrome 3
    • Carney complex 3
    • MEN-1 and MEN-1-like diseases (MEN4, MEN5) 3
    • Familial isolated pituitary adenomas (FIPA) 2

Physiological and Technical Causes of Falsely Elevated Results

  • Normal adolescence: GH suppression is difficult to achieve during puberty, particularly in mid-puberty (Tanner stages 2-3) 3
  • Poorly controlled diabetes mellitus: Can cause falsely elevated IGF-1 levels 3
  • Hepatic or renal failure: May spuriously elevate IGF-1 3
  • Pre-analytical and assay variability: Technical issues can produce discordant results 4

Diagnostic Evaluation Algorithm

Step 1: Measure Age- and Sex-Adjusted Serum IGF-1

IGF-1 is the most reliable initial screening marker for GH excess and should be measured first. 3, 2

  • An elevated age-adjusted and sex-adjusted IGF-1 strongly supports the diagnosis of acromegaly 3
  • IGF-1 alone is sufficient to establish the diagnosis in the majority of clinically suspected cases with clear elevation 5
  • Critical interpretation caveats:
    • IGF-1 may be falsely low or normal despite true GH excess in: severe hypothyroidism, malnutrition, severe infection 3
    • IGF-1 may be falsely elevated without GH excess in: poorly controlled diabetes, hepatic failure, renal failure 3
    • Oral estrogen therapy reduces hepatic IGF-1 production and can mask GH excess 3
    • Significant inter-assay variability requires use of locally validated reference ranges 3

Step 2: Perform Oral Glucose Tolerance Test (OGTT) with Serial GH Measurements

If IGF-1 is elevated, confirm the diagnosis with an OGTT measuring GH at baseline and serially after glucose load. 3

  • Diagnostic criterion: Failure to suppress GH below 1 μg/L (or <0.4 μg/L with sensitive assays) after oral glucose load confirms GH excess 3
  • In healthy adults, GH should suppress to these levels after glucose administration 3
  • Important limitation: The OGTT has limited diagnostic value in patients with only mildly elevated GH output, as up to 52% of patients with biochemically active acromegaly but GH <4.3 μg/L may show GH nadir <1 μg/L 6
  • The correlation between post-glucose GH nadir and IGF-1 is strongest in patients with lower baseline GH levels 6

Step 3: Obtain Pituitary MRI with Contrast

  • Contrast-enhanced pituitary MRI is the imaging modality of choice for detecting somatotroph adenomas once biochemical GH excess is confirmed 2
  • Assess tumor volume, extension, and potential mass effects on surrounding structures 1

Step 4: Assess Other Pituitary Hormones

Evaluate for co-secretion and mass-effect-induced hypopituitarism, as 25-35% of patients with somatotrophinomas have hypofunction of other pituitary hormones. 3

  • Prolactin: Hyperprolactinemia occurs in 65% of cases due to co-secretion or stalk compression 3
  • TSH and free T4: To identify hypothyroidism (which can confound IGF-1 interpretation) or TSH co-secretion 3
  • LH, FSH, and sex hormones: To detect hypogonadism from mass effect 3
  • ACTH and cortisol: To evaluate for hypopituitarism or rare co-secretion 3

Step 5: Screen for Syndromic Causes

Perform clinical evaluation for associated syndromic diseases, particularly in younger patients or those with family history. 3

  • Genetic testing is recommended when syndromic features are present 2
  • Specific syndromes to consider:
    • McCune-Albright: Café-au-lait macules, fibrous dysplasia, precocious puberty 3, 2
    • Carney complex: Skin pigmentation, cardiac/cutaneous myxomas, testicular/adrenal disease 3, 2
    • MEN-1: Screen for pancreatic GHRH-secreting tumors 3

Step 6: Assess Complications of GH Excess

  • Cardiovascular: Echocardiography for left ventricular hypertrophy and diastolic dysfunction; blood pressure monitoring for hypertension 3, 1
  • Metabolic: Fasting glucose, HbA1c, or OGTT for glucose intolerance and diabetes mellitus 3, 1
  • Respiratory: Sleep study if obstructive sleep apnea is suspected 1
  • Musculoskeletal: Assess for arthropathy and carpal tunnel syndrome 1

Treatment Options

First-Line: Transsphenoidal Surgery

  • Transsphenoidal surgery is the first-line treatment for most patients with GH-secreting pituitary adenomas 1
  • Surgery aims to excise the adenoma and normalize GH/IGF-1 levels 1
  • Higher baseline GH levels predict lower likelihood of surgical remission 3

Medical Therapy

Medical therapy is indicated for post-operative residual disease, surgical contraindications, or patient preference. 3, 1

  • Somatostatin analogs (octreotide, lanreotide, pasireotide): First-line medical therapy 1
  • GH receptor antagonist (pegvisomant): Used in patients resistant to somatostatin analogs 1
  • Combination therapy: May be required for optimal control 3

Radiotherapy

  • Radiotherapy is used when surgery and medical therapy fail to achieve adequate GH/IGF-I control 1
  • Delayed onset of effect (years) limits its use as primary therapy 1

Monitoring Strategy

Monitor both GH and IGF-1 at baseline and during follow-up, as they provide complementary information about disease activity. 3

  • IGF-1 levels correlate linearly with GH only up to approximately 4 μg/L, then plateau around 10 μg/L 3
  • Baseline GH levels predict surgical outcome and are key to monitoring adenoma activity 3
  • Treatment goals: normalize age-adjusted IGF-1 and achieve GH <1 μg/L (or <0.4 μg/L with sensitive assays) 1, 7

Critical Pitfalls to Avoid

  • Do not rely on IGF-1 alone without considering confounding factors: Thyroid status, nutritional state, diabetes control, liver/kidney function, and estrogen use all affect IGF-1 interpretation 3
  • Do not dismiss modest IGF-1 elevation: Patients with early or partially treated acromegaly may have only mildly elevated IGF-1 but still have active disease 4, 5
  • Do not over-interpret OGTT results in patients with mild GH elevation: The test has limited utility when baseline GH is only mildly elevated (<4.3 μg/L), as many such patients may show "normal" suppression despite biochemically active disease 6
  • Do not forget to screen for hormone co-secretion: Prolactin co-secretion occurs in the majority of cases and requires specific management 3
  • Do not overlook ectopic GHRH secretion: Consider this diagnosis if pituitary imaging is normal or shows hyperplasia rather than adenoma, particularly in patients with MEN-1 3
  • Do not neglect assessment of complications: Cardiovascular, metabolic, and respiratory complications determine long-term prognosis and require systematic evaluation 3, 1

References

1
Research

Acromegaly.

Orphanet journal of rare diseases, 2008

2
Guideline

Timing of GH Excess Determines Gigantism vs. Acromegaly

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

4
Research

Biochemical discrepancies in the evaluation of the somatotroph axis: Elevated GH or IGF-1 levels do not always diagnose acromegaly.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2022

5
Research

Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2012

Related Questions

What causes an elevated Insulin-like Growth Factor-1 (IGF-1) level in a 71-year-old female?
Why are CT scans and GnRH used for elevated IGF-1 levels?
What are the steps for diagnosing and treating acromegaly, including initial diagnostic tests such as insulin-like growth factor 1 (IGF-1) levels and oral glucose tolerance test (OGTT)?
What does it mean to have elevated Insulin-like Growth Factor-1 (IGF-1) levels?
What blood tests should be ordered to screen for acromegaly?
Is cetirizine contraindicated in patients with glucose‑6‑phosphate dehydrogenase deficiency?
For an adult with type 2 diabetes and obesity (moderate renal impairment), how does tirzepatide compare to semaglutide regarding HbA1c reduction, weight loss, dosing, safety, and renal considerations?
What is the appropriate management for a patient presenting with anasarca?
In an older adult with fever and acute delirium but no focal neurologic deficits, trauma, or anticoagulation, is an emergent head CT required?
When should a corneal abrasion be referred to an ophthalmologist?
What is the investigation of choice for suspected ovarian torsion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question